TEVA Stock Overview
Teva Pharmaceutical Industries Limited desarrolla, fabrica, comercializa y distribuye medicamentos genéricos, medicamentos especializados y productos biofarmacéuticos en Norteamérica, Europa, Israel y a escala internacional.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Teva Pharmaceutical Industries Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$53.14 |
| 52 Week High | US$53.79 |
| 52 Week Low | US$26.37 |
| Beta | 1.06 |
| 1 Month Change | 11.83% |
| 3 Month Change | 26.31% |
| 1 Year Change | 56.43% |
| 3 Year Change | 47.37% |
| 5 Year Change | 2.23% |
| Change since IPO | 476.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| TEVA | IL Pharmaceuticals | IL Market | |
|---|---|---|---|
| 7D | 2.4% | 1.0% | -0.9% |
| 1Y | 56.4% | -15.3% | 13.1% |
Rentabilidad frente al sector: TEVA superó al sector IL Pharmaceuticals , que obtuvo un rendimiento del -52% el año pasado.
Rentabilidad vs. Mercado: TEVA superó al mercado IL, que obtuvo un rendimiento del -8.8% el año pasado.
Price Volatility
| TEVA volatility | |
|---|---|
| TEVA Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in IL Market | 8.1% |
| 10% least volatile stocks in IL Market | 3.0% |
Precio estable de las acciones: El precio de las acciones de TEVA ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de TEVA (5%) se ha mantenido estable durante el año pasado.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1901 | 35,737 | Richard Francis | https://www.tevapharm.com |
Teva Pharmaceutical Industries Limited desarrolla, fabrica, comercializa y distribuye medicamentos genéricos, medicamentos especializados y productos biofarmacéuticos en Norteamérica, Europa, Israel y a escala internacional. Ofrece medicamentos genéricos en diversas formas farmacéuticas, como comprimidos, cápsulas, inyectables, inhalantes, líquidos, parches transdérmicos, pomadas y cremas; productos estériles, hormonas, medicamentos de alta potencia y sustancias citotóxicas en formas farmacéuticas parenterales y sólidas; y productos genéricos con dispositivos médicos y productos combinados. La empresa se centra en las áreas del sistema nervioso central (SNC), respiratorio y oncología.
Teva Pharmaceutical Industries Limited Fundamentals Summary
| TEVA fundamental statistics | |
|---|---|
| Market cap | ₪59.14b |
| Earnings (TTM) | -₪2.07b |
| Revenue (TTM) | ₪58.67b |
1.0x
P/S Ratio-28.5x
P/E RatioIs TEVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TEVA income statement (TTM) | |
|---|---|
| Revenue | US$15.85b |
| Cost of Revenue | US$8.20b |
| Gross Profit | US$7.65b |
| Other Expenses | US$8.21b |
| Earnings | -US$559.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.50 |
| Gross Margin | 48.25% |
| Net Profit Margin | -3.53% |
| Debt/Equity Ratio | 244.1% |
How did TEVA perform over the long term?
See historical performance and comparison